Table 4. IP cycle administration and tolerability.

Measurement	Number (%)
Tolerability
Cycles prescribed	328
Cycles completed	261 (80)
Patients completing all IP cycles	39 (65)
Dose delay, reduction or alteration
Delay >1 week (total)	13
Reduction	6 (10)
Alteration (total)	38
Reason for stopping therapy
Completion	39 (65)
Toxicity	20 (33)
Response plateau	1 (2)
Response
Complete	53 (88)
Partial	4 (7)
Progression	3 (5)
Status
No evidence of disease	26 (43)
Alive with disease	14 (23)
Deceased	16 (27)
Unknown	4 (7)